Michael G. Kauffman
2018
In 2018, Michael G. Kauffman earned a total compensation of $2.3M as Chief Executive Officer at Karyopharm Therapeutics, a 14% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $268,625 |
|---|---|
| Option Awards | $1,444,660 |
| Salary | $550,000 |
| Other | $11,660 |
| Total | $2,274,945 |
Kauffman received $1.4M in option awards, accounting for 64% of the total pay in 2018.
Kauffman also received $268.6K in non-equity incentive plan, $550K in salary and $11.7K in other compensation.
Rankings
In 2018, Michael G. Kauffman's compensation ranked 5,071st out of 14,244 executives tracked by ExecPay. In other words, Kauffman earned more than 64.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,071 out of 14,244 | 64th |
Division Manufacturing | 1,907 out of 5,759 | 67th |
Major group Chemicals And Allied Products | 699 out of 2,122 | 67th |
Industry group Drugs | 585 out of 1,811 | 68th |
Industry Pharmaceutical Preparations | 450 out of 1,385 | 68th |
Source: SEC filing on April 19, 2019.
Kauffman's colleagues
We found four more compensation records of executives who worked with Michael G. Kauffman at Karyopharm Therapeutics in 2018.
News
Karyopharm Therapeutics CEO Richard Paulson receives $8.4M in 2021
April 8, 2022
Karyopharm Therapeutics CEO Michael Kauffman's 2020 pay jumps 22% to $3.9M
April 7, 2021
Karyopharm Therapeutics CEO Michael Kauffman's 2019 pay jumps 42% to $3.2M
April 9, 2020
Karyopharm Therapeutics Executive Vice President, Chief Commercial Officer Anand Varadan receives $2.3M in 2018
April 19, 2019